Pharmaron (康龙化成) A+H Listing: 3Q2019 Numbers and Thoughts on Valuation
Pharmaron, a leading contract research company, is looking to list in Hong Kong by raising up to USD 600 million. In our previous note, we have...
552 Views
Pharmaron Beijing IPO: Solid 9M19, but Is It Good Enough?
Pharmaron Beijing Co., Ltd. (A) (300759 CH) is a global contract research organisation (CRO) and is one of the top three drug discovery service...
407 Views
WuXi Biologics Placement: An Attractive Opportunity
Wuxi Biologics (Cayman) Inc (2269 HK) is a global one-stop biologics services provider and often referred to as CRO (contract research...
391 Views
Wuxi Biologics Placement: A Larger Deal but Performance Track Record Weighs
Wuxi Biologics is looking to raise upto US$770m by selling 35 million primary shares and selling 35million shares held by its main shareholder Wuxi...
522 Views
Shanghai/Shenzhen Connect Ideas: Wuliangye Vs Moutai (2019-08-23)
In our weekly Shanghai/Shenzhen Connect Ideas series, we aim to help our investors understand the flow of northbound trades via the Shanghai and...
448 Views